Compound News and Research

RSS

Spice turmeric corrects the cystic fibrosis defect

Scientists at The Hospital for Sick Children (Sick Kids) and Yale University School of Medicine have found that a compound in the spice turmeric corrects the cystic fibrosis defect in mice. This research is reported in the April 23, 2004 issue of the journal Science.

24 Apr 2004

Idebenone continues to show promise in treating Friedreich’s ataxia (FA)

Idebenone, a compound similar to coenzyme Q10, continues to show promise in treating the heart complications of Friedreich's ataxia (FA), notes correspondence published in the Feb. 10 issue of Neurology.

23 Apr 2004

Potential new drug may slow the progression of the Parkinson's disease

An international team of Parkinson's disease researchers has shown that a potential new drug is effective at treating patients in the early stages of Parkinson's and may even slow the progression of the disease. The results from the Parkinson Study Group are in the April 19 issue of the Archives of Neurology.

22 Apr 2004

Turmeric corrects the cystic fibrosis defect

22 Apr 2004

The Alzheimer's Society receives lottery money for stem cell research

The Alzheimer's Society is to receive a grant of more than £200,000 from the Community Fund for stem cell research into potential treatments for Alzheimer’s disease.

21 Apr 2004

New drug is effective at treating patients in the early stages of Parkinson’s

An international team of Parkinson’s disease researchers has shown that a potential new drug is effective at treating patients in the early stages of Parkinson’s and may even slow the progression of the disease.

20 Apr 2004

Cognitive Neuroscientists Reveal Creative Brain Processes

Think Isaac Newton getting hit on the head with an apple or Alexander Graham Bell inventing the telephone. While these creative or “Aha!” moments often are associated with scientific discoveries and inventions, most people occasionally feel the thrill of insight when a solution that had eluded them suddenly becomes obvious.

20 Apr 2004

Myriad Genetics advances drug for chemotherapy-induced nausea

Myriad Genetics, Inc. today released new data on MPC-4505, its Neurokinin-1 (NK1) receptor antagonist, a drug candidate for chemotherapy-induced nausea and vomiting (emesis). MPC-4505 is a potent, orally bioavailable, CNS-penetrating, highly selective NK1 antagonist.

20 Apr 2004

Curry offers possible protection against Alzheimer’s disease

A new study has found that curry, a common and popular cooking additive, could be an effective enhancer of an enzyme that protects the brain against oxidative conditions.

19 Apr 2004

Wine, beer and tea have contributed to a significant decrease in breast cancer

Numerous studies have been published showing that consuming alcohol increases the risk for breast cancer. That’s what makes a new research finding from Portugal so intriguing. The study has determined that certain compounds found in wine, beer (and tea) have contributed to a significant decrease in breast cancer cell proliferation.

19 Apr 2004

World's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube

Nuevolution A/S, a privately held drug discovery company today announced that it has generated what it believes to be the world's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube.

19 Apr 2004

Researchers find drug that may suppress genetic mutation using a novel screening approach

Researchers at Massachusetts General Hospital have developed a way of identifying promising new drugs that may get around a major challenge in drug discovery.

18 Apr 2004

Citrus soda culprit in patient’s medical mystery

It took a team of medical sleuths at Vanderbilt University Medical Center to get to the bottom of what was causing the 35-year-old to have abnormal blood chemistries during a post-transplant check up.

16 Apr 2004

Patient uses inorganic blood substitute

A patient who is losing large amounts of blood presents a medical emergency, requiring proper blood-typing and immediate access to multiple units of compatible blood.

16 Apr 2004

Cinnamon's role as an insulin substitute in type II diabetes

Cinnamon may be more than a spice – it may have a medical application in preventing and combating diabetes. Cinnamon may help by playing the role of an insulin substitute in type II diabetes, according to cellular and molecular studies at the University of California, Santa Barbara, Iowa State University and the U.S. Department of Agriculture.

14 Apr 2004

Compound in ventolin inhalers could make asthma worse

A chemical used in the leading brand of asthma inhaler could actually make the allergy worse, say scientists. They fear a compound in Ventolin inhalers may react with steroids used to prevent attacks.

13 Apr 2004

Natural medication shown to not always be a safe alternative to synthetic medication

The common perception that if medication is natural then it must be safe has recently come under fire from a researh by a Consumer Reports magazine. The consumer publication found a dozen herbal supplements, some banned in Asia, Europe and Canada but widely available in the United States, may cause cancer, kidney or liver damage and even death.

10 Apr 2004

New process to extract proteins from membranes by using chemicals

Proteins are complex compounds that are essential for the growth and repair of tissue. While scientists understand much about the structure and stability of water-soluble proteins that ‘float’ around in humans, they know very little about the shape and stability of proteins that are embedded, or folded, into the lipid membrane of cells. Such membrane proteins make up about 30 percent of all proteins in the body.

8 Apr 2004

Celadrin arthritis topical cream significantly reduces pain

Celadrin is a novel compound developed through a proprietary process. The product is an all-natural ingredient which has been clinically shown to provide joint health, flexibility and improved quality of life on a cumulative basis with no reported side effects.

7 Apr 2004

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004